Abstract:Significant advances have occurred in the knowledge of the pathogenesis of ARDS. It is now recognized that ARDS is a manifestation of a diffuse process that results from a complicated cascade of events following an initial insult or injury. Mechanical ventilation and PEEP are still important components of supportive therapy. To avoid ventilator-associated lung injury there is emphasis on targeting ventilator management based on measurement of pulmonary mechanics. For those with resistant hypoxia and severe pulmonary hypertension adjunctive modalities, such as prone positioning and low-dose iNO, may provide important benefit. Alternative modes of supporting gas exchange, such as with partial liquid ventilation and extracorporeal gas-exchange, may serve as rescue therapies. Advances in cell and molecular biology have contributed to a better understanding of the role of inflammatory cells and mediators that contribute to the acute lung injury and the pathophysiology of the syndrome that manifests as ARDS. Based on this new understanding, the potential targets for intervention to ameliorate the systemic inflammatory response have proliferated. Examples include the cytokine network and its receptors, antioxidants, and endothelins. Apart from the challenge of testing these agents in experimental models, it seems likely that determination of the optimum combination of agents will become an equally important endeavor. A particular challenge is to develop better methods of predicting which of the many at-risk patients will go on to full-blown ARDS and MODS, thereby targeting subgroups of patients most likely to benefit from anti-inflammatory therapies. Similarly, the adverse effects of immunosuppressive therapy may be diminished by improved, perhaps molecular, techniques to detect microbial pathogens and permit differentiation between Systemic inflammatory response syndrome and sepsis.

Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

Novel Biomarkers for Acute Respiratory Distress Syndrome: Genetics, Epigenetics and Transcriptomics

Pharmacotherapy of acute respiratory distress syndrome

Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Pulmonary drug delivery for acute respiratory distress syndrome

Opportunities for improved clinical trial designs in acute respiratory distress syndrome

The Acute Respiratory Distress Syndrome in 2013

Advances in Biomarkers for Diagnosis and Treatment of ARDS

Using the sympathetic system, beta blockers and alpha-2 agonists, to address acute respiratory distress syndrome

Analytics with Artificial Intelligence to Advance the Treatment of Acute Respiratory Distress Syndrome

Management of the acute respiratory distress syndrome

Acute Respiratory Distress Syndrome:The Past, Current Status and Prospect

Recent advances in the understanding and management of ARDS

Optimization of Acute Respiratory Distress Syndrome Therapy Strategies with Advances of Pathophysiology

Acute respiratory distress syndrome

Emerging application of nanomedicine-based therapy in acute respiratory distress syndrome

Biomarkers of Acute Respiratory Distress Syndrome: Current State and Future Prospects

Redox signaling and antioxidant therapies in acute respiratory distress syndrome

Precision Medicine in Acute Respiratory Distress Syndrome: Progress, Challenges, and the Road ahead

Advancing precision medicine for acute respiratory distress syndrome